Delivery Order SPE2DB24D8003-SPE2DB25FJTSH
Award Date
1/27/25
Potential Completion Date
1/28/25
Potential Value
$1.9K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, identified as SPE2DB24D8003|SPE2DB25FJTQS, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $2,523.29 firm fixed-price delivery order is for the provision of Dupixent 300 mg/2 ml syringes, a pharmaceutical product. The contract is not set aside and is part of a larger Indefinite Delivery Contract (IDC) vehicle, SPE2DB24D8001, valued at $999,999,999.00, which allows Dakota Drug, Inc. to deliver a...
This is a $3,056.09 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of Dupixent 300 mg/2 ml syringes, with a performance period extending through February 12, 2025. Dakota Drug, Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, that allows the company to provide a comprehensive range of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of Dupixent 300 mg/2 ml syringes to support military medical operations. The contract has a ceiling value of $5,495.39 and a performance period extending through January 21, 2025. Dakota Drug, Inc. also holds a larger indefinite delivery contract (IDC) with the DLA, valued at $999,999,999.00, which...
The U.S. government's Defense Logistics Agency (DLA) awarded a $26,588.72 firm-fixed-price delivery order contract (SPE2DX15D8003|SPE2DX24F7D7B) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml syringes. The contract has a performance period through May 8, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (SPE2DB24D8001) as part of the DLA's ECAT...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has a ceiling value of $7,469.04 and a period of performance ending on September 17, 2024. Dakota Drug, Inc. is a prime contractor to the DLA Troop Support Medical, playing a crucial role in supporting the medical supply chain operations for...
This is a federal contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml syringes. The contract, identified as SPE2DX15D8003|SPE2DX24F7C1H, has a ceiling value of $23,631.00 and a completion date of December 27, 2023. The contract is a Delivery Order with a Firm Fixed Price pricing type. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $7,091.73 to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. This contract, with a performance period ending on March 4, 2024, is for the delivery of Dupixent 300 mg/2 ml syringes. This award is part of a larger Indefinite Delivery Contract (IDC), identified as SPE2DB24D8001, which allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, involves the delivery of Dupixent 300 mg/2 ml syringes to the Defense Logistics Agency (DLA) Troop Support Medical division. The contract has a firm fixed price of $2,345.09 and a period of performance through November 15, 2023. This award is part of Dakota Drug's larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00, which allows the company...
This federal contract award was made by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml pens. The contract, identified as SPE2DB24D8001|SPE2DB25FKZCU, has a ceiling value of $6,688.11 and a period of performance through January 30, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00, which is part of the DLA Troop Support Medical's ECAT...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $4,070.96 firm fixed-price delivery order is for the pharmaceutical product DUPIXENT 300 mg/2 ml syringe, with a completion date of February 4, 2025. This order is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division under the ECAT Generation V Program, which allows the...